Companies - Fagron

Price

 
Price
-
Change
-
Change %
-
Open
-
High
-
Low
-
Volume
-

Profile

 
Profile
Fagron is specialized in the development, sale and distribution of personal care products and services intended for professionals in the health sector (doctors, pharmacists, dentists, hospitals, nursing homes, etc.).
Industry
Pharmaceutical
Description
Companies in the pharmaceutical industry develop and sell drugs. In addition, licenses on newly developed drugs are sold to other companies. Medications are strictly supervised by different supervisors. This, and the complex process of developing new drugs results in the long development time before a product makes it to the market. Companies that develop new drugs benefit from long-term protection of their products through patents. This allows them to make money on a new drug.

Key figures (2017)

 
The ratios below are calculated using the last known share price and the last known company financials.

Ratios per share

Price to Earnings
17,575
Price to Earnings (3 years)
-14,557
Price to Earnings (5 years)
-22,179
Price to earnings growth
-
Price/cashflow
12,771
Price/net cashflow
-3,537
Price/book value
-
Price to sales
1,857

Ratios for dividend

Dividend yield
-
Pay out
-

Valuation ratios

Market value/PE
-
Market value/turnover
1,857
Enterprise value/turnover
1,725

Return ratios

Return on private equity
-
Return on total equity
7,85%
Profit margin
10,57%

Risk ratios

Solvability
-
Solvability
-
Current ratio
1,538
Debt to Equity
-

Value invest ratios

Grahams Number
-
Grahams Value
-
Grahams Product
-
Grahams Product (3 years)
-

2017

 

Profit and loss

Net profit (x 1 mln)
€ 46,66
Turnover (x 1 mln)
€ 441,55
Cashflow(x 1 mln)
€ 64,21
Net cashflow(x 1 mln)
€ -231,88

Balance

Private equity (x 1 mln)
-
Foreign equity (x 1 mln)
-
Current assets (x 1 mln)
€ 166,43
Current liabilities (x 1 mln)
€ 108,24
Working capital (x 1 mln)
€ 58,19
Balance total (x 1 mln)
€ 594,05

Share

Outstanding shares (x 1 mln)
71,840
Price year-end
€ 11,42
Dividend per share
-
Earnings per share
€ 0,65
Cashflow per share
€ 0,89
Net cashflow per share
€ -3,23
Book value per share
-
Stockmarket value (x 1 mln)
€ 820,05

History

 
Year
2017
2016
2015
2014
2013
Net profit (x 1 mln)
€ 46,66
€ -20,56
€ -195,10
€ 16,23
€ -32,10
Turnover (x 1 mln)
€ 441,55
€ 425,05
€ 481,66
€ 450,41
€ 387,18
Price year-end
€ 11,42
€ 9,71
€ 6,81
€ 6,81
€ 6,81
Year high
€ 13,74
€ 10,59
€ 6,81
€ 6,81
€ 6,81
Year low
€ 8,84
€ 3,79
€ 6,81
€ 6,81
€ 6,81
Outstanding shares (x 1 mln)
71,840
53,957
31,304
31,431
30,647
Price to Earnings
17,575
-25,490
-1,093
13,188
-6,502
Earnings per share
€ 0,65
€ -0,38
€ -6,23
€ 0,52
€ -1,05
Dividends
-
-
-
€ 1,00
€ 0,72
Dividend yield
-
-
-
14,68%
10,57%
Pay out
-
-
-
193,66%
-68,74%
Private equity (x 1 mln)
-
€ 152,88
€ -64,77
€ 156,95
€ 155,17
PE per share
-
€ 2,83
€ -2,07
€ 4,99
€ 5,06
Balance total (x 1 mln)
€ 594,05
€ 852,84
€ 689,38
€ 973,75
€ 804,69
Stockmarket value (x 1 mln)
€ 820,05
€ 524,08
€ 213,18
€ 214,05
€ 208,71

Company analysis

 

Analysis of profit indicators

Average profit per share (6 years)
€ -0,69
Standard deviation average profit
€ 2,63 (-382,32%)
Average annual growth rate
-47,08%
Compound annual growth percentage
-5,90%
© 2009 Skuzet. All Rights Reserved.